High NOP2 expression was associated with shorter overall survival (OS) in 11 cancer types and poorer disease-free survival (DFS) in 13 cancer types (P < 0.05), including renal cell carcinomas, hepatocellular carcinoma, lower-grade glioma, and lung adenocarcinoma. Here, NOP2 is linked to central nervous system cancer.